Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 83% Improvement Relative Risk Lawrie et al. Ivermectin for COVID-19 META ANALYSIS Favors ivermectin Favors control
Ivermectin reduces the risk of death from COVID-19 – a rapid review and meta-analysis in support of the recommendation of the Front Line COVID-19 Critical Care Alliance
Lawrie et al., Preprint (Preprint) (meta analysis)
Lawrie et al., Ivermectin reduces the risk of death from COVID-19 – a rapid review and meta-analysis in support of the.., Preprint (Preprint) (meta analysis)
Jan 2021   Source   PDF  
  All Studies   Meta
Meta analysis confirming the effectiveness of ivermectin for COVID-19, showing ivermectin treatment mortality relative risk RR 0.17 [0.18-0.35] and prophylaxis cases RR 0.12 [0.08-0.18].
Currently there are 95 ivermectin studies and meta analysis shows:
Mortality51% lower [37‑62%]
Ventilation29% lower [13‑42%]
ICU admission41% lower [16‑58%]
Hospitalization34% lower [20‑45%]
Cases78% fewer [67‑85%]
risk of death, 83.0% lower, RR 0.17, p < 0.001, treatment 8 of 585 (1.4%), control 44 of 522 (8.4%), NNT 14.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lawrie et al., 3 Jan 2021, preprint, 1 author.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: Research for Impact 03 January 2021 URGENT COVID-19 information: Ivermectin reduces the risk of death from COVID-19 – a rapid review and meta-analysis in support of the recommendation of the Front Line COVID-19 Critical Care Alliance. Tess Lawrie MBBCh, PhD; E-BMC Ltd, Office 305, Northgate House, Upper Borough Walls, Bath, United Kingdom Email: Website: ORCID iD 0000-0002-5500-8590 Background to this rapid review Recently a group of expert critical care physicians, called the Front Line COVID-19 Critical Care Alliance (FLCCC), reviewed the evidence on the effects of ivermectin on SARS-CoV-2 virus and COVID-19 infections.1 They concluded that the evidence on ivermectin “demonstrates a strong signal of therapeutic efficacy” and recommended that ivermectin is adopted globally and systematically for the prophylaxis and treatment of COVID-19.1 Ivermectin is an anti-parasitic medication widely used in low- and middle-income countries to treat parasitic worm infections in adults and children.1,2 Having been used for decades for this purpose, it is considered extremely safe and effective2,3 and has an increasing list of indications due to its antiviral and anti-inflammatory properties.4 On the WHO’s Model List of Essential Medicines it is retained in the form of a 3 mg tablet.5 For parasitic infections in adults, ivermectin is commonly administered as a single 12 mg oral dose (0.2mg/kg). The FLCCC review summarizes the findings of 27 studies evaluating ivermectin for prophylaxis and treatment of COVID-19 infection; however, it does not include metaanalyses for the majority of outcomes. The FLCCC has called upon national and international health care agencies to devote the necessary resources to checking and confirming this groundbreaking evidence. Given the urgency of the situation, I undertook this rapid systematic review and metaanalysis of studies included in the FLCCC paper to validate the FLCCC’s conclusions. Target audience This report is aimed primarily at health professionals and policymakers. Methodology Study selection, data extraction and outcome measures I From this list, I included randomized controlled trials (RCTs) and controlled observational studies (OCTs), excluding case-control studies and case series due to their higher risk of bias. I extracted data on the characteristics of the studies, risk of bias and important COVID-19 health outcomes (see Box 1), which I compiled with reference to the FLCCC review tables. Risk of study bias was assessed using the Cochrane Handbook for Systematic Reviews of Interventions and the ROBINS-I tools for RCTs and OCTs, respectively.6,7 Box 1. COVID-19 outcome measures A: Ivermectin treatment versus control 1. Death (primary outcome) 2. Condition improvement, as measured by the study authors 3. Condition deterioration, as measured by the study authors 4. Recovery time, in days 5. Length of hospital stay, in days 6. Admission to hospital (for outpatient treatment) 7. Admission to ICU or requiring ventilation 8. Serious adverse events B. Ivermectin prophylaxis versus control 1. COVID-19 infection, defined as a positive COVID-19 test with or without symptoms (primary outcome) 2. Serious adverse events Data analysis and evidence quality assessment 2 I used Review Manager (RevMan) software version 5.4 for..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop